LAG3 checkpoint function and its mechanism of action in therapeutic targeting
- 9 October 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- p. 1-15
Abstract
No abstract availableKeywords
This publication has 150 references indexed in Scilit:
- Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapyBioorganic & Medicinal Chemistry, 2024
- Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapyActa Pharmaceutica Sinica B, 2023
- Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptorEuropean Journal of Immunology, 2020
- A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responsesActa Pharmaceutica Sinica B, 2020
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1Cancer Cell, 2018
- Regulation of T Cell Receptor Activation by Dynamic Membrane Binding of the CD3ɛ Cytoplasmic Tyrosine-Based MotifCell, 2008
- A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptorsCancer Letters, 2006
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003
- Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)European Journal of Immunology, 2002
- CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteinsEuropean Journal of Immunology, 1995